Sparsentan Safety and the REMS Monitoring Requirement in FSGS

In "Sparsentan Safety and the REMS Monitoring Requirement in FSGS," the panel examines the safety profile behind sparsentan and the REMS program clinicians must follow.

Dr. Campbell turns to DUPLEX safety data, noting at least one adverse event occurred in both cohorts, with a comparable 93.5% of sparsentan patients and 93% of irbesartan patients affected overall. The most common events, including COVID-19, peripheral edema, hypotension, hyperkalemia, diarrhea, and anemia, were balanced between arms, and no hepatotoxicity signal emerged despite the theoretical class risk tied to endothelin receptor antagonists. Dr. Trachtman explains that sparsentan carried extra scrutiny because earlier endothelin antagonists were linked to substantial liver injury, but its high selectivity for the endothelin type A receptor over type B appears to be a key reason serious adverse events stayed low. He adds a personal note, having cared for seven patients across the earlier DUET and DUPLEX trials, all of whom tolerated the drug well over years of follow-up.

Despite this reassurance, sparsentan still requires a REMS program mandating fixed-frequency monitoring, a regulatory pattern Dr. Trachtman compares to tolvaptan's REMS requirement in polycystic kidney disease, also tied to liver injury risk. He notes the burden has already eased, shifting from monthly to quarterly liver function testing, and argues that frequency doesn't diverge dramatically from how often nephrologists already see FSGS patients in practice. Dr. Trachtman frames the REMS program as the FDA staying vigilant while real-world data accumulates, rather than a sign of concern, and suggests that if community experience continues to support the drug's safety, monitoring frequency could eventually be reduced further, or the requirement reconsidered altogether. For now, he emphasizes, there's no signal of elevated hepatotoxicity risk specific to sparsentan, which should reassure clinicians and managed care professionals evaluating the drug for their patient populations.

Our next episode, "FSGS Payer Policy: Aligning Coverage with the Sparsentan Label," turns to how the FDA label and the trial's own subgroup data should shape payer policy.